-
The HIV community has waited a long time but there might finally be some rewards when the first microbicide options become available worldwide. Among these options are an intravaginal ring that delivers dapivirine and the daily use of tenofovir vaginal gel.
-
After a rocky decade, the microbicides field finally is seeing some success, opening up a promising future that should include a wider range of HIV prevention options for women as well as for men who have sex with men (MSM).
-
The Food and Drug Administration (FDA) approved changes to the labeling for entecavir (Baraclude®) to provide a dosing regimen for adult patients with chronic hepatitis B (HBV) and decompensated liver disease, based on efficacy data through Week 48 and cumulative safety data from one trial.
-
The Centers for Disease Control and Prevention is issuing $11.6 million in grants to support demonstration projects that implement a combination approach to HIV prevention inclusive of treatment, care, and social services in 12 hard-hit areas across the country.
-
A national study has found that antiretroviral therapy (ART) drugs are underused among people who seek HIV care from HIV clinics at seven sites across the United States.
-
Young minority men who have sex with men (MSM) are most at risk of HIV infection in the United States, so there needs to be more prevention options and strategies addressing their vulnerability. Microbicides may be an answer.
-
You have just taken sign-out when a nurse comes up to you and says that there is a 64-year-old man in the critical bay who took an overdose of his medications. The patient has a history of hypertension, atrial fibrillation, and depression. The patient is lethargic but arousable, and reports he took about 40 tablets of immediate-release metoprolol three hours ago in an attempt to "end it all." The nurses are starting IV lines, checking vitals, and putting the patient on the monitor. You wonder, "Is it too late for gastric decontamination? If he is symptomatic, which therapy will I try first, and what are my options?"
-
-
In this issue: Tiotropium for uncontrolled asthma, sibutramine pulled from market, incidence and mortality data from WHI, FDA Actions.
-
Following a chart review that indicated few (24%) medical ICU (MICU) patients received consultation for physical therapy (PT) or occupational therapy (OT) a percentage almost 50% lower than at two other academic medical centers in the same city as well as a higher prevalence of deep sedation, the authors elected to initiate a QI project designed to reduce the use of deep sedation and improve patients' functional ability.
